ArticleNPJ precision oncology2026
Germline haploinsufficiency of MUTYH causes mutational signature SBS18 in multiple tumour types and specifically raises colorectal cancer risk.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The MUTYH base excision repair protein corrects oxidative DNA damage. Bi-allelic germline MUTYH mutations cause a rare, Mendelian recessive syndrome of colorectal adenomas, duodenal polyps and colorectal cancer (CRC), in which tumours have excess somatic C:G > A:T mutations and the mutational signature SBS36. Signature SBS18, which resembles SBS36, is common in sporadic CRCs and other cancers. Increased risks of CRC and other cancers have been reported in germline MUTYH heterozygotes (mono-allelic mutation carriers, frequency 2-3%), but the existence of these associations and underlying mechanism have remained controversial. Compared with MUTYH-wildtype individuals, CRCs from MUTYH heterozygotes had ~2.5-fold excess of signature SBS18, increased C:G > A:T transversions (including in driver genes) and raised mutation burden. These observations resulted from MUTYH haploinsufficiency, rather than somatic loss of the wildtype allele, contrary to previous suggestions. Hypermutation probably begins before cancer initiation. In a case-control analysis, we found approximately 1.4-fold elevated risk of CRC in MUTYH heterozygotes, causally mediated through increased SBS18. The association between MUTYH heterozygosity and SBS18 was also present in many extra-colonic cancers, including other gastrointestinal tumours, but the raised SBS18 did not detectably increase the risk of these cancers. Germline heterozygotes for another base excision repair gene, MBD4, showed equivalent associations for SBS1, C:G > T:A mutations and CRC risk. Mutational signatures in cancers can result in part from non-rare germline variation in DNA repair. The specific effect of MUTYH heterozygosity on CRC risk plausibly reflects the high baseline levels of oxidative damage and SBS18 activity in the colorectum.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.